Statement re Media Comment

RNS Number : 2330O

Omega Diagnostics Group PLC

08 February 2021

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Statement re. media comment

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the article published online yesterday by the Financial Times.

The Company can confirm that it is continuing to modify its Alva-based facility to upscale significantly its lateral flow test production capacity. When contracts or supply agreements are signed to utilise this capacity the Company will announce this in line with AIM disclosure obligations.

Contacts: 

Omega Diagnostics Group PLC	Tel: [phone]
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd	Tel: [phone]
Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane (ECM)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

 

END

 

 

SPCBUGDDRBGDGBR